A Study of RG1662 in Adults and Adolescents With Down Syndrome (CLEMATIS)
Status:
Completed
Trial end date:
2016-05-04
Target enrollment:
Participant gender:
Summary
This multi-center, randomized, double-blind, 3-arm, parallel-group, placebo-controlled study
will evaluate the efficacy and safety of RG1662 in adults and adolescents with Down syndrome.
Subjects will be randomized to receive RG1662 either at low or high dose or placebo orally
twice daily for 26 weeks.